Biomarker-driven therapy in endometrial cancer

医学 子宫内膜癌 彭布罗利珠单抗 微卫星不稳定性 内科学 肿瘤科 癌症 曲妥珠单抗 乳腺癌 免疫疗法 基因 生物化学 微卫星 等位基因 化学
作者
Hannah Karpel,Brian M. Slomovitz,Robert L. Coleman,Bhavana Pothuri
出处
期刊:International Journal of Gynecological Cancer [BMJ]
卷期号:33 (3): 343-350 被引量:10
标识
DOI:10.1136/ijgc-2022-003676
摘要

This article reviews treatments and targets of interest in endometrial cancer by molecular subtype. The Cancer Genome Atlas (TCGA) classifies four molecular subtypes-mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H); copy number high (CNH)/p53abn; copy number low (CNL)/no specific molecular profile (NSMP); and POLEmut-which are validated and highly prognostic. Treatment consideration by subtype is now recommended. In March and April 2022, respectively, the US Food and Drug Administration (FDA) fully approved and the European Medicines Agency adopted a positive opinion recommending the anti-programmed cell death protein-1 (PD-1) antibody pembrolizumab for advanced/recurrent dMMR/MSI-H endometrial cancer which has progressed on or following a platinum-containing therapy. A second anti-PD-1, dostarlimab, received accelerated approval by the FDA and conditional marketing authorization by the European Medicines Agency in this group. The combination of pembrolizumab/lenvatinib for mismatch repair proficient/microsatellite stable endometrial cancer, including p53abn/CNH and NSMP/CNL, received accelerated FDA approval in conjunction with Australia's Therapeutic Goods Administration and Health Canada in September 2019. The FDA and European Medicines Agency made full recommendations in July 2021 and October 2021. Trastuzumab is National Comprehensive Cancer Network (NCCN) compendium listed for human epidermal growth factor receptor-2-positive serous endometrial cancer, which is primarily within the p53abn/CNH subtype. In addition to hormonal therapy, maintenance therapy with selinexor (exportin-1 inhibitor) showed potential benefit in p53-wildtype cases in a subset analysis and is being investigated prospectively. Other treatment regimens being evaluated in NSMP/CNL are hormonal combinations with cyclin-dependent kinase 4/6 inhibitors and letrozole. Ongoing trials are evaluating immunotherapy in combination with frontline chemotherapy and other targeted agents. Treatment de-escalation is being evaluated in POLEmut cases given its favorable prognosis with or without adjuvant therapy. Molecular subtyping has important prognostic and therapeutic implications, and should guide patient management and clinical trial design in endometrial cancer, which is a molecularly driven disease.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI2S应助资紫丝采纳,获得10
1秒前
满意之玉发布了新的文献求助10
2秒前
满意之玉完成签到,获得积分10
8秒前
朴实问筠完成签到 ,获得积分10
8秒前
怡然的一凤完成签到 ,获得积分10
8秒前
王俊凯的科妍通完成签到 ,获得积分10
10秒前
研友_ZzrWKZ完成签到 ,获得积分10
12秒前
slsdianzi完成签到,获得积分10
23秒前
physicalproblem完成签到,获得积分10
24秒前
rayzhanghl完成签到,获得积分10
25秒前
松松包完成签到,获得积分10
25秒前
帅气的祥完成签到,获得积分10
26秒前
32秒前
EiketsuChiy完成签到 ,获得积分0
33秒前
书生也是小郎中完成签到 ,获得积分10
35秒前
二十八画生完成签到 ,获得积分10
36秒前
一心完成签到,获得积分10
38秒前
眠眠清完成签到 ,获得积分10
40秒前
优雅的千雁完成签到,获得积分10
45秒前
昌化古天乐完成签到 ,获得积分10
45秒前
Phoenix ZHANG完成签到 ,获得积分10
58秒前
聚乙二醇完成签到 ,获得积分10
1分钟前
经纲完成签到 ,获得积分0
1分钟前
1分钟前
FashionBoy应助科研通管家采纳,获得10
1分钟前
薰硝壤应助科研通管家采纳,获得10
1分钟前
Jasper应助科研通管家采纳,获得10
1分钟前
天天开心完成签到 ,获得积分10
1分钟前
小丸子完成签到 ,获得积分10
1分钟前
WANG完成签到,获得积分10
1分钟前
cripple发布了新的文献求助10
1分钟前
abc完成签到 ,获得积分10
1分钟前
sdbz001完成签到,获得积分10
1分钟前
平常的羊完成签到 ,获得积分10
1分钟前
奥里给完成签到 ,获得积分10
1分钟前
gYang完成签到,获得积分10
1分钟前
Akim应助柳绿柳采纳,获得10
1分钟前
七子完成签到 ,获得积分10
1分钟前
初七完成签到 ,获得积分10
1分钟前
1分钟前
高分求助中
좌파는 어떻게 좌파가 됐나:한국 급진노동운동의 형성과 궤적 2500
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Cognitive linguistics critical concepts in linguistics 800
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
氟盐冷却高温堆非能动余热排出性能及安全分析研究 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3052652
求助须知:如何正确求助?哪些是违规求助? 2709891
关于积分的说明 7418319
捐赠科研通 2354494
什么是DOI,文献DOI怎么找? 1246122
科研通“疑难数据库(出版商)”最低求助积分说明 605951
版权声明 595921